Nasdaq btai.

A great week that adds to BioXcel Therapeutics, Inc.'s (NASDAQ:BTAI) one-year returns, institutional investors who own 48% must be happy (Simply Wall St.) Dec-22-22 07:00AM BioXcel Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +6.25%.BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience. The Company’s drug re-innovation ...Jun 29, 2023 · BTAI stock is down 57.2% as of Thursday morning. That comes as some 3.2 million shares change hands, as compared to its daily average trading volume of about 549,000 shares. Investors seeking out ... Back to BTAI Overview About Latest Pre-Market Trades Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day.

The average one-year price target for BioXcel Therapeutics (NASDAQ:BTAI) has been revised to 14.28 / share. This is an increase of 5.88% from the prior estimate of 13.49 dated October 31, 2023.

BXCL701 is an oral small molecule inhibitor of a class of enzymes called DPPs, specifically DPP8/9 and DPP4. Inhibition of DPP8/9 initiates the activation of the inflammasome and ultimately the activation of the innate immune system. BXCL701 is being developed by OnkosXcel Therapeutics, a wholly owned, clinical-stage subsidiary of …

Aug 16, 2022 · The big shareholder groups in BioXcel Therapeutics, Inc. (NASDAQ:BTAI) have power over the company. Generally speaking, as a company grows, institutions will increase their ownership. Conversely ... BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology.BioXcel Therapeutics, Inc. (NASDAQ:BTAI) dropped 21.2% to settle at $27.21 after Goldman Sachs downgraded the stock from Buy to Sell and lowered its price target from $55 to $24.BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q3 2023 Earnings Call Transcript November 14, 2023 BioXcel Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-1.72 EPS, expectations were $-1.29. Operator: Good morning, and welcome to the BioXcel Therapeutics Conference Call, which will cover its alignment with the FDA on its ...

21 Feb 2023 ... BioXcel Therapeutics, Inc. [BTAI] Rings the Nasdaq Closing Bell.

BioXcel Therapeutics, Inc. (BTAI). NASDAQ: BTAI · IEX Real-Time Price · USD.

Investors, who purchased BioXcel Therapeutics, Inc. (NASDAQ: BTAI) shares prior to December 2021 and continue to hold any of those NASDAQ: BTAI shares, also have certain options and should contact ...BTAI's recent financials show a net loss of $53.5MM for 2Q23, with a cash reserve expected to last until mid-2024. Strategic financing negotiations are underway. We maintain a hold rating on ...BTAI DEADLINE: ROSEN, ... (NASDAQ: BTAI) between... BTAI: 3.93 (+2.61%) BIOXCEL DEADLINE ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In BioXcel To Contact Him Directly To Discuss Their Options PR Newswire - Sat Sep 2, 6:00AM CDT ...NEW HAVEN, Conn., Oct. 31, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in ...BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience. The Company’s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning ...

Nov 7, 2023 · In the last trading session, 7.87 million shares of the BioXcel Therapeutics Inc (NASDAQ:BTAI) were traded, and its beta was 0.87. Most recently the company’s share price was $4.79, and it changed around $0.15 or 3.23% from the last close, which brings the market valuation of the company to $140.20M. BTAI currently trades at a discount to its ... NEW HAVEN, Conn., Feb. 23, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial ...The average one-year price target for BioXcel Therapeutics (NASDAQ:BTAI) has been revised to 14.28 / share. This is an increase of 5.88% from the prior estimate of 13.49 …Investors, who purchased BioXcel Therapeutics, Inc. (NASDAQ: BTAI) shares prior to December 2021 and continue to hold any of those NASDAQ: BTAI shares, also have certain options and should contact ...Get a brief overview of BioXcel Therapeutics, Inc. financials with all the important numbers. View the latest BTAI income statement, balance sheet, and financial ratios.BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience. The Company’s drug re-innovation ...

Nov 30, 2023 · Philadelphia, Pennsylvania--(Newsfile Corp. - November 29, 2023) - A recently filed securities fraud class action complaint alleges that BioXcel Therapeutics Inc. (NASDAQ: BTAI), via certain ... NEW HAVEN, Conn., Jan. 11, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative ...

By David Bautz, PhD NASDAQ:BTAI READ THE FULL BTAI RESEARCH REPORT Business Update Positive Topline Results for TRANQUILITY II; Possible Trial Conduct Issues at One Clinical Site On June 29, 2023 ...BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience. The Company’s drug re-innovation ...NEW HAVEN, Conn., Oct. 31, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in ...NEW HAVEN, Conn., May 14, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial ...BioXcel Therapeutics, Inc. Common Stock (BTAI) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.According to the issued ratings of 7 analysts in the last year, the consensus rating for BioXcel Therapeutics stock is Hold based on the current 5 hold ratings and 2 buy ratings for BTAI. The average twelve-month price prediction for BioXcel Therapeutics is $23.88 with a high price target of $40.00 and a low price target of $11.00.Investigation Alert BAX, DHR, BTAI, and IBRX: Johnson Fistel, LLP Encourages Long-Term Investors to Submit Their Information Below GlobeNewswire Sep 26, 2023 4:27pm Trading Information

BioXcel Therapeutics, Inc. (BTAI.NASDAQ) : Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock BioXcel Therapeutics, ...

BioXcel Therapeutics Inc stock price live 3.79, this page displays NASDAQ BTAI stock exchange data. View the BTAI premarket stock price ahead of the market session or assess the after hours quote.

Find the latest Earnings Report Date for BioXcel Therapeutics, Inc. Common Stock (BTAI) at Nasdaq.com.OnkosXcel is a subsidiary of BioXcel Therapeutics, Inc. (Nasdaq: BTAI). This press release is being made pursuant to, and in accordance with, Rule 135 under the Securities Act of 1933, ...Nov 17, 2023 · On November 17, 2023, BTAI’s average trading volume was 3.13M shares. BTAI) stock’s latest price update. The stock of BioXcel Therapeutics Inc (NASDAQ: BTAI) has decreased by -0.47 when compared to last closing price of 4.25.Despite this, the company has seen a loss of -18.18% in its stock price over the last five trading days. Nov 26, 2023 · Allogene Therapeutics (NASDAQ:) is a clinical-stage biotech firm specializing in developing allogeneic T cell cancer treatment therapies. Around 67.4% of ALLO’s share count consists of publicly ... BioXcel Therapeutics (NASDAQ: BTAI) is another of the low-float, heavily-shorted penny stocks in the biotech space. Based on its “about us” page, BioXcel is riding the coattails of “AI Mania ...The three major U.S. stock exchanges are the New York Stock Exchange (NYSE), the NASDAQ and the American Stock Exchange (AMEX). As of 2014, the NYSE is the largest and most prestigious of the three. The NASDAQ is a virtual stock exchange.BioXcel Therapeutics, Inc. (NASDAQ:BTAI) said the FDA has accepted for filing the new drug application for BXCL501, its investigational, orally dissolving thin film formulation of dexmedetomidine ...NEW HAVEN, Conn., May 02, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative ...BTAI's recent financials show a net loss of $53.5MM for 2Q23, with a cash reserve expected to last until mid-2024. Strategic financing negotiations are underway. We maintain a hold rating on ...Alliancebernstein Now Owns 0.10% of BioXcel Therapeutics (BTAI) Feb 9, 2023.

BioXcel Therapeutics, Inc. Common Stock (BTAI) After-Hours Stock Quotes - Nasdaq offers after-hours quotes and extended trading activity data for US and global markets.NEW HAVEN, Conn., July 09, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence ...OnkosXcel is a subsidiary of BioXcel Therapeutics, Inc. (Nasdaq: BTAI). This press release is being made pursuant to, and in accordance with, Rule 135 under the Securities Act of 1933, ...0. On November 15, 2023, BioXcel Therapeutics (NASDAQ:BTAI) shared its Q3 earnings results. Let’s take a closer look at the key takeaways from the announcement: – Earnings: BioXcel Therapeutics fell short of estimated earnings by 20.61%, reporting an EPS of $-1.58 compared to the estimated $-1.31. This represents a significant deviation ...Instagram:https://instagram. reed inc stocksandstorm stockwalmart downtown chicagospdr sandp regional banking etf NEW HAVEN, Conn., Feb. 23, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative ...14 Aug 2023 ... BioXcel Therapeutics (BTAI 2.37%) stock is plummeting Monday. The clinical ... NASDAQ: BTAI. BioXcel Therapeutics. Today's Change. (2.37%) $0.09. current mortgage rates in tennesseehome mortgage loans for small business owners NEW HAVEN, Conn., Jan. 11, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative ... strive etf On November 17, 2023, BTAI’s average trading volume was 3.13M shares. BTAI) stock’s latest price update. The stock of BioXcel Therapeutics Inc (NASDAQ: BTAI) has decreased by -0.47 when compared to last closing price of 4.25.Despite this, the company has seen a loss of -18.18% in its stock price over the last five trading days.Fintel reports that on May 30, 2023, HC Wainwright & Co. reiterated coverage of BioXcel Therapeutics (NASDAQ:BTAI) with a Buy recommendation. Analyst Price Forecast Suggests 187.47% Upside. As of ...'Dividend-growth stocks tend to be less volatile than the overall stock market,' the research firm notes. ALBBAXLAD · REAL ESTATE. 8 ...